Today

Nanobiotix issued ADSs, ordinary shares and pre-funded warrants, increasing dilution.

FINS sold 2.0M Series A preferred shares for $50M; purchaser gets two board seats.

Sold unregistered Class I shares and declared three monthly distributions.

Board stopped the RockawayX deal after finding material inconsistencies in RockawayX's financials.

Kyivstar disclosed it paid $80.8M to buy six Lviv solar plants, expanding green energy capacity and hedging electricity costs.

Nasdaq issued a Staff Delisting Determination after Vestand missed multiple 10-Q and 10-K filings.

Lincoln completed its IPO, raised $473.7M, and established public corporate structure.

BurTech closed an $80M IPO and funded a trust for a future business combination.

Shareholders approved a 3.8M-share increase to the company equity plan and officer exculpation amendment.

Company closed $225M convertible notes offering, creating potential equity dilution.

Azul's ADSs begin trading on NYSE American on June 1, 2026.

Quanterix named Anthony Catalano COO with cash and RSU compensation.

Trinseo and certain affiliates filed Chapter 11 under a prepackaged RSA to implement a $2.0B debt reduction.

Trimble director Mark Peek resigned; audit committee chair replaced amid remediation of material weaknesses.

EMAT received a Nasdaq notice for a late 10-Q but cured the deficiency and regained compliance.

Cycurion agreed to acquire Halo Privacy and integrate havenX for cash, stock, and contingent payments.

Positive Phase 3 VALOR results; NDA planned for 1H 2026.

Randomized Phase 2b showed statistically significant influenza prevention and clean safety.

Phase 1 patient data show strong IRAK4 knockdown and Sanofi will advance KT-474 to Phase 2.

FDA cleared the IND for SER-252, enabling a planned Phase 1b registrational study.